What is Aperiomics?
Aperiomics operates at the intersection of big data and molecular biology, providing a unique platform that identifies every known bacterium, virus, fungus, and parasite. By utilizing a proprietary database of nearly 40,000 microorganisms, the company offers medical professionals an unprecedented level of diagnostic clarity. This technology is essential for identifying the root causes of infections that remain elusive under standard clinical protocols, thereby streamlining the path to effective patient outcomes. Recognized as a leader in life science innovation, Aperiomics is fundamentally changing the standard of care for infectious disease management.
How much funding has Aperiomics raised?
Aperiomics has raised a total of $3.7M across 3 funding rounds:
Angel/Seed
$512K
Series A
$3M
Debt
$169K
Angel/Seed (2017): $512K with participation from Pipeline Angels
Series A (2020): $3M led by Propel(X), The Launch Place, Pipeline Angels, Atlanta Technology Angels, Venture South, and Central Texas Angel Network
Debt (2021): $169K supported by PPP
Key Investors in Aperiomics
The Launch Place
The Launch Place offers consulting, mentoring, and training services aimed at supporting startups and small businesses through their seed fund and entrepreneurial events.
Atlanta Technology Angels
Atlanta Technology Angels is a leading angel investor network in Georgia that supports startup and early-stage technology companies with financial investments and mentorship.
Central Texas Angel Network
Central Texas Angel Network is a prominent angel investment firm based in Austin that connects high-net-worth individuals with promising startups to foster regional economic growth.
What's next for Aperiomics?
With this latest round of financing, Aperiomics is well-positioned to scale its operations and further integrate its metagenomic sequencing platform into global clinical workflows. The strategic focus will likely center on expanding the utility of its proprietary database and enhancing the speed of diagnostic reporting. As the company moves beyond its initial development phase, the focus shifts toward commercial expansion and solidifying its market position as the premier provider of comprehensive pathogen identification. The continued support from its diverse investor base provides the necessary runway to pursue these ambitious growth objectives in the competitive biotech sector.
See full Aperiomics company page
